1. Use of β-D-glucan in diagnosis of suspected Pneumocystis jirovecii pneumonia in adults with HIV infection
- Author
-
Stephen Morris-Jones, Thomas Juniper, Emmanuel Q Wey, Frank A. Post, Chris P Eades, Killian Quinn, Robert F. Miller, Rebecca Gorton, Eliza Gil, and Harriet Fodder
- Subjects
0303 health sciences ,030306 microbiology ,business.industry ,Pneumocystis jirovecii Pneumonia ,Public Health, Environmental and Occupational Health ,Human immunodeficiency virus (HIV) ,Dermatology ,medicine.disease_cause ,medicine.disease ,Pneumocystis pneumonia ,respiratory tract diseases ,Elevated serum ,03 medical and health sciences ,β d glucan ,0302 clinical medicine ,Infectious Diseases ,Immunology ,medicine ,Biomarker (medicine) ,Pharmacology (medical) ,030212 general & internal medicine ,business ,Pneumonitis - Abstract
Objectives: An elevated serum (1-3)-β-D-glucan (BDG) concentration has high sensitivity for a diagnosis of Pneumocystis pneumonia (PCP) in people with HIV (PWH). At the current manufacturer-recommended positive threshold of 80 pg/mL (Fungitell), specificity for PCP is variable and other diagnostic tests are required. We evaluated the utility of serum BDG for diagnosis of suspected PCP in PWH at three inner-London hospitals to determine BDG concentrations for diagnosis and exclusion of PCP. Methods: From clinical case records, we abstracted demographic and clinical information and categorised patients as having confirmed or probable PCP, or an alternative diagnosis. We calculated sensitivity, specificity and positive predictive value (PPV) of serum BDG concentrations >400 pg/mL and negative predictive value (NPV) of BDG 400 pg/mL had a sensitivity of 83%, specificity of 97% and PPV 97% for diagnosis of PCP; BDG 400 pg/mL effectively confirm the diagnosis. Values 80–400 pg/mL should prompt additional diagnostic tests.
- Published
- 2021
- Full Text
- View/download PDF